See How Many Clients You're Missing Each Month

Simply enter your business email & Topline AI Agent will show you.

Bio

Generated by
Topline AI
Lizzie H. Li is a renowned expert in precision medicine and personalized healthcare, with a strong background in biomarker-targeted drug development, nanotechnology, and cancer biology. As a Postdoc Fellow at AstraZeneca, she has developed and delivered innovative diagnostic assays, nanopore sensing technologies, and biomarker detection methods. Her research expertise includes bioconjugate click chemistry, ADC preparation, and characterization, with a focus on tumour-selective and HER2-targeted delivery. Li holds a Doctor of Philosophy degree from Peking University and a Bachelor's degree in Chemistry from Renmin University of China.

Experience

  • AstraZeneca
    • Cambridge, England, United Kingdom
    • Postdoc Fellow
      • May 2020 - Present
      • Cambridge, England, United Kingdom

      - Diagnostic assay development from proof-of-concept study, feasibility study and validation on clinical samples;- Nanopore sensing of analyte selectively and specifically in complex biomatrix;- Biomarker detection in liquid biopsy samples;- DNA extraction, purification manually or using automated machines such as KingFisher, and downstream analysis using Tape Station and qPCR;- Built knowledge, experience and passion in developing and delivering precision medicine/personalized healthcare to revolutionize the treatment to patients.

    • Marie Sklodowska-Curie Fellow
      • Dec 2016 - Mar 2020

      - Awarded Marie Sklodowska-Curie Fellowship for 2 years. Wrote the research proposal independently;- Built knowledge and expertise in biomarker-targeted drug development, bioconjugate click chemistry, ADC preparation, characterization and safety, efficacy evaluation in vivo;- Focused on tumour-selective and HER2-targeted delivery with improved safety and efficacy; fluorescent imaging and quantification of tumour tissue with low background in vivo; - Collaborative work on developing novel site-specific ADC, activities including ADC preparation, characterization and safety, efficacy evaluation in normal and HER2-overexpress cancer cells; - Expertise in small molecules, protein and protein-drug conjugates analysis using NMR and LC-MS; evaluation of drug safety and toxicity on cancer cell lines; evaluation of biomarker expression in living/fixed tissues.

  • Peking University
    • Beijing City, China
    • Research Associate
      • Sep 2014 - Sep 2016
      • Beijing City, China

      - Built knowledge and expertise in nanotechnology, cancer biology, molecular biology and chemical biology;- Focused on tumour-targeted protein delivery and subsequential in situ activation with NIR light in living cells and in mice, enabling tumour treatment and imaging with precise spatiotemporal control; - Extensive experience in tissue culture, cancer cell signalling pathway analysis by immunostaining, Western Blot, Flow Cytometry, fluorescence microscope imaging and quantification, handling nanomaterial and bioconjugate chemistry;- Experience in LC-MS analysis, molecular biology, tumour resection from mice xenograft tumour model, tumour tissue sectioning and microscope imaging.

Education

  • 2008 - 2014
    Peking University
    Doctor of Philosophy - PhD, Chemical Biology
  • 2004 - 2008
    Renmin University of China
    Bachelor's degree, Chemistry

Suggested Services

This profile is unclaimed. These are suggested service rates with 0% commision upon successful connection

Industry Focus. “Pharmaceutical Manufacturing”

Looking to Create a Custom Project?

Need a custom project? We'll create a solution designed specifically for your project.

Get Started

References

Social Profiles

Community

You need to have a working account to view this content. Click here to join now

Similar Profiles